不同剂量低分子肝素治疗子痫前期伴胎儿生长受限的效果

Effect of different doses of low molecular weight heparin in the treatment of preeclampsia with fetal growth restriction

目的探讨不同剂量低分子肝素治疗子痫前期伴胎儿生长受限的效果。方法选取2017年4月至2018年2月我院收治的58例子痫前期伴胎儿生长受限患者为研究对象,采取随机数字表法将其分为观察组与对照组,各29例。观察组给予常规治疗+5 000 IU/d低分子肝素治疗,对照组采用常规治疗+2 500 IU/d低分子肝素治疗。比较两组治疗效果。结果治疗后,两组胎儿的股骨长、双顶径及头围均优于治疗前,且观察组优于对照组(P<0.05)。观察组新生儿出生后体重、可安慰性、前臂弹回及手握持评分均明显高于对照组(P<0.05)。结论高剂量低分子肝素治疗子痫前期伴胎儿生长受限可有效促进胎儿发育、改善胎儿预后,且安全性较高,值得临床推广与应用。

Objective To investigate the effect of different doses of low molecular weight heparin in the treatment of preeclampsia with fetal growth restriction. Methods Fifty-eight patients of preeclampsia with fetal growth restriction were selected in our hospital from April 2017 to February 2018 as the result objects. Patients were divided into observation group and control group according to random number table method, with 29 cases in each group. The observation group was treated with routine treatment plus 5 000 IU/d low molecular weight heparin, while the control group was treated with routine treatment plus2 500 IU/d low molecular weight heparin. The therapeutic effects of the two groups were compared. Results After treatment, the femoral length, biparietal diameter and head circumference of the two groups were better than those before treatment, and those in the observation group were better than the control group (P<0.05). The postnatal weight, the scores of consolability, forearm rebound and hand holding of newborns in the observation group were significantly higher than those in the control group (P<0.05). Conclusion High dose low molecular weight heparin in the treatment of preeclampsia with fetal growth restriction can effectively promote fetal development, improve fetal prognosis, and has high safety, which is worthy of clinical promotion and application.